- Home
- SABS vs APM Comparison
SABS vs APM Comparison
Compare SABS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- APM
- Stock Information
- Founded
- SABS 2014
- APM 2010
- Country
- SABS United States
- APM United Kingdom
- Employees
- SABS N/A
- APM N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- APM Health Care
- Exchange
- SABS Nasdaq
- APM Nasdaq
- Market Cap
- SABS 15.8M
- APM 18.9M
- IPO Year
- SABS N/A
- APM 2018
- Fundamental
- Price
- SABS $2.28
- APM $1.85
- Analyst Decision
- SABS Strong Buy
- APM
- Analyst Count
- SABS 5
- APM 0
- Target Price
- SABS $10.00
- APM N/A
- AVG Volume (30 Days)
- SABS 85.9K
- APM 20.3M
- Earning Date
- SABS 11-05-2025
- APM 04-30-2025
- Dividend Yield
- SABS N/A
- APM N/A
- EPS Growth
- SABS N/A
- APM N/A
- EPS
- SABS N/A
- APM N/A
- Revenue
- SABS $114,698.00
- APM N/A
- Revenue This Year
- SABS N/A
- APM N/A
- Revenue Next Year
- SABS N/A
- APM N/A
- P/E Ratio
- SABS N/A
- APM N/A
- Revenue Growth
- SABS N/A
- APM N/A
- 52 Week Low
- SABS $1.00
- APM $0.46
- 52 Week High
- SABS $6.60
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SABS 54.42
- APM 50.26
- Support Level
- SABS $2.03
- APM $1.64
- Resistance Level
- SABS $2.34
- APM $1.90
- Average True Range (ATR)
- SABS 0.12
- APM 0.36
- MACD
- SABS 0.02
- APM -0.06
- Stochastic Oscillator
- SABS 84.00
- APM 18.38
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.